Healthcare / BiotechnologyKSE
$13950.00
-1000.00 (-6.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $5.8B · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$837.1B
P/E
20.8x
↑EV/EBITDA
21.7x
↑ROE
32.5%
↑Gross Margin
44.4%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+23.8%
FCF CAGR
—
FCF margin
29.4%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $114.06B · net income $40.29B · FCF $33.56B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $114.06B | $114.06B | $64.85B | $56.23B | $60.18B |
| Net Income | $40.29B | $40.29B | $6.33B | $3.58B | $8.26B |
| EBITDA | $37.95B | $37.95B | $9.43B | $8.44B | $8.90B |
| EPS | 671.00 | 671.00 | 106.00 | 60.00 | 138.00 |
| Gross Margin | 44.4% | 44.4% | 32.9% | 27.6% | 39.6% |
| Operating Margin | 30.1% | 30.1% | 7.2% | 2.3% | 14.7% |
| Net Margin | 35.3% | 35.3% | 9.8% | 6.4% | 13.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.01 | 0.04 | 0.22 |
| Current Ratio | 1.34 | 1.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $33.56B | $33.56B | $-840.0M | $5.79B | $-11.04B |
| Returns | |||||
| ROE | 32.5% | 32.5% | 7.3% | 4.5% | 10.8% |
| Valuation | |||||
| P/E | 20.79 | 20.79 | 80.28 | 101.17 | 75.72 |
| EV/EBITDA | 21.70 | 21.70 | 53.11 | 41.62 | 70.57 |
| P/B | 6.76 | 6.76 | 5.88 | 4.50 | 8.16 |
| Growth & Yield | |||||
| Revenue Growth | 75.9% | 75.9% | 15.3% | -6.6% | — |
| EPS Growth | 533.0% | 533.0% | 76.7% | -56.5% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
22.6%
EPS terminal req.
$1237.83
Spread vs growth
510.4%
5Y implied EPS CAGR
17.4%
EPS terminal req.
$1497.77
Spread vs growth
515.6%
10Y implied EPS CAGR
13.6%
EPS terminal req.
$2412.18
Spread vs growth
519.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+29.6%
Start / end P/E
101.8x → 20.8x
EPS bridge
106.00 → 671.00
Residual
-424.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.